基于SEER数据库的血液肿瘤研究现状  

Research status of hematological malignancies based on SEER database

作　　者：田颖 黄俊华[1] 杨婉浠 唐文娇 徐才刚[1] Tian Ying;Huang Junhua;Yang Wanxi;Tang Wenjiao;Xu Caigang(Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan Province,China)

机构地区：[1]四川大学华西医院血液科,成都610041

出　　处：《国际输血及血液学杂志》2024年第6期467-471,共5页International Journal of Blood Transfusion and Hematology

基　　金：四川省科技厅重点研发项目(2019YFS0027);四川大学华西医院2024年住院医师/专科医师科研基金项目。

摘　　要：血液肿瘤,特别是罕见血液肿瘤,由于其发病率较低,相关研究数据有限,导致在流行病学、临床特征及患者预后评估研究方面存在较大挑战。如何提高这些患者的生存率、改善预后依然是临床亟待解决的难题。基于美国国家癌症研究所"监测、流行病学与最终结果"(SEER)数据库的血液肿瘤相关研究,能够提供较为可靠和广泛的数据支持,从而获得更具可信度的结论。笔者拟就近年来基于SEER数据库的血液肿瘤研究现状进行阐述,探索相关研究的发展方向,旨在为研究者提供研究思路和方向。Hematologic malignancies,particularly rare hematologic malignancies,present significant challenges in epidemiological,clinical,and patients′prognostic studies due to their low incidence and limited research data.Improving survival rates and prognostic outcomes for these patients remains a critical clinical issue.Research of hematological malignancies based on the Surveillance,Epidemiology,and End Results(SEER)database from the National Cancer Institute provides more reliable and comprehensive data support,thereby enabling the derivation of more credible conclusions.This article aims to elaborate on research status of hematologic malignancy using SEER data,explore the future directions of related studies,and provide valuable insights and guidance for researchers in this field.

关 键 词：血液肿瘤 流行病学 治疗 危险因素 预后 SEER数据库 

分 类 号：R733[医药卫生—肿瘤]